The FDA approved Zenbexus oral therapy for multiple myeloma, coinciding with disclosures regarding insider buying and selling transactions.
2 reports, 2 independent
Updated Sep 7
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA approved Zenbexus oral therapy for multiple myeloma, coinciding with disclosures regarding insider buying and selling transactions.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Insider sale disclosed in SEC filing involving Bristol-Myers Squibb.Sub-event
FDA approved Zenbexus oral therapy for multiple myeloma; insider trading disclosed.1 source
Keep exploring
The entities involved
- FDA
-
Bristol-Myers Squibb
American pharmaceutical company
-
SEC
Slovak company